LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

Home・Listă Acțiuni・Fate Therapeutics Inc

Fate Therapeutics Inc

Închisă

SectorSănătate

2.39 -1.65

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

2.31

Maxim

2.39

Indicatori cheie
By Trading Economics
Venit	-124K -32M
Vânzări	-372K 1.4M
EPS	-0.27
Marjă de profit	-2,364.792
Angajați	161
EBITDA	-13M -42M

Recomandări
By TipRanks
Recomandări	Cumpărare
Prognoză pe 12 luni	+109.21% upside

Dividende
By Dow Jones
Următoarele câștiguri	11 mai 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	35M 209M
Deschiderea anterioară	4.04
Închiderea anterioară	2.39

Sentimentul știrilor

By Acuity

50%

192 / 347 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

0.9101 / 1.14 Suport & Rezistență

Fate Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

8 mai 2026, 23:55 UTC

Câștiguri

Review & Preview: Still Going Strong -- Barrons.com

8 mai 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

8 mai 2026, 20:49 UTC

Câștiguri

Why the Gap Between Chip and Software Stocks Keeps Getting Wider -- Barrons.com

8 mai 2026, 20:25 UTC

Câștiguri

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8 mai 2026, 19:43 UTC

Câștiguri

Cencosud 1Q Rev $4.565B >CENCOSUD.SN

8 mai 2026, 19:43 UTC

Câștiguri

Cencosud 1Q Net $115M

8 mai 2026, 19:20 UTC

Market Talk

Oil Futures End Session Higher, But Down on the Week -- Market Talk

8 mai 2026, 19:18 UTC

Câștiguri

Monster and Celsius Earnings Show Energy-Drink Fatigue Is Far From Over -- Barrons.com

8 mai 2026, 19:16 UTC

Câștiguri

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8 mai 2026, 19:08 UTC

Câștiguri

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8 mai 2026, 19:05 UTC

Câștiguri

Investors Feared Energy-Drink Fatigue. Monster and Celsius Earnings Offered Reassurance. -- Barrons.com

8 mai 2026, 19:02 UTC

Market Talk

U.S. Natural Gas Futures Little Changed on Week -- Market Talk

8 mai 2026, 18:51 UTC

Câștiguri

Memory Stocks Continue to Surge. What's Driving Micron and Sandisk Higher. -- Barrons.com

8 mai 2026, 18:49 UTC

Câștiguri

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8 mai 2026, 18:41 UTC

Câștiguri

McDonald's Stock Rises on Earnings Beat. The Value Push Needs to Maintain Momentum. -- Barrons.com

8 mai 2026, 17:38 UTC

Market Talk

U.S. Oil Rig Count Rises By 2 to 410 -- Market Talk

8 mai 2026, 17:14 UTC

Câștiguri

How High Gas Prices Need to Rise to Boost Electric Vehicle Sales -- Barrons.com

8 mai 2026, 17:04 UTC

Market Talk

Zcash Caps Off Parabolic Week -- Market Talk

8 mai 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

8 mai 2026, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

8 mai 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

8 mai 2026, 15:39 UTC

Market Talk

Gold Seen Transitioning Away From 'Corrective Phase' -- Market Talk

8 mai 2026, 15:39 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8 mai 2026, 15:39 UTC

Market Talk

Canada's Job Market Sees Worst Start in Years -- Market Talk

8 mai 2026, 15:36 UTC

Market Talk

A Jump in Canada's Jobless Rate May Turn Out to Be a Blip -- Market Talk

8 mai 2026, 15:20 UTC

Market Talk

'Altcoin Season' Indicator on the Rise -- Market Talk

8 mai 2026, 15:20 UTC

Market Talk

Câștiguri

Enbridge Gas Pipelines, Distribution Units Drive 1Q Beat -- Market Talk

8 mai 2026, 15:05 UTC

Market Talk

Bitcoin Slips Back Below the $80k Mark -- Market Talk

8 mai 2026, 14:42 UTC

Market Talk

Tough Times for Canadian Teenagers Looking for Work -- Market Talk

8 mai 2026, 14:39 UTC

Market Talk

Canadian Labor Market Suggests Persistent Higher Inflation Unlikely -- Market Talk

Comparație

Modificare preț

Fate Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

109.21% sus

Prognoză pe 12 luni

Medie 5 USD 109.21%

Maxim 7 USD

Minim 2 USD

În baza a 5 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruFate Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

5 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 5 analiști care au acordat evaluări ale acțiunilor Fate Therapeutics Inc - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

0.9101 / 1.14Suport & Rezistență

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

192 / 347 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.